Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 8Thoracic 1Sarcoma 1NET 1Head & Neck 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 1863Lung Neoplasms 1292Small Cell Lung Carcinoma 324Colorectal Neoplasms 273Breast Neoplasms 242Melanoma 221Neoplasms 215Ovarian Neoplasms 192Neoplasm Metastasis 182Pancreatic Neoplasms 155Squamous Cell Carcinoma of Head and Neck 150Stomach Neoplasms 141Head and Neck Neoplasms 121Carcinoma, Renal Cell 119Triple Negative Breast Neoplasms 109Esophageal Neoplasms 108Prostatic Neoplasms 106Endometrial Neoplasms 98Uterine Cervical Neoplasms 96Urinary Bladder Neoplasms 87Colonic Neoplasms 87Mesothelioma 86Mesothelioma, Malignant 80Carcinoma, Hepatocellular 74Brain Neoplasms 70Sarcoma 63Disease 62Adenocarcinoma of Lung 59Carcinoma, Transitional Cell 54Gastrointestinal Neoplasms 50

Interventions

repotrectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Intestinal Diseases × Thoracic × 1 year × Clear all
NCT03093116 2026-05-27

TRIDENT-1

Turning Point Therapeutics, Inc.

Phase 1/2 Recruiting
500 enrolled 2 FDA
EndocrineGastrointestinalHead & NeckNETSarcomaThoracic

Adenocarcinoma, Bronchial Neoplasms, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Colonic Diseases, Colonic Neoplasms, Digestive System Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Sarcoma, Thoracic Neoplasms, Thyroid Diseases, Thyroid Neoplasms, Neuroectodermal Tumors, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡